Signals from a pivotal trial now cut through the noise of a crowded obesity market, forcing hard questions about where dual agonists belong and how quickly they can reshape care. Obesity has shifted from a lifestyle narrative to a biologic disease with organ-level consequences, most notably in the
A disease that steals movement while leaving thought intact demanded more than incremental symptom care, and that urgency set the stage for a candidate built to confront the fault line where motor neurons first begin to fail. AP-2, now entering first-in-human testing at La Princesa University
Hospitals feel the squeeze as drug-resistant infections outpace discovery, while conventional screening drains time and money without delivering medicines that dissolve, distribute, and survive the real world. That pressure has pushed researchers to reimagine how drugs are created, trading
Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into
Long after scales celebrate a hard-won weight loss, the immune system can keep score in subtler ways, storing traces of past obesity inside helper T cells as molecular marks that linger and continue to shape health in the background. This emerging insight reframes obesity as more than excess fat;
Decades of Alzheimer’s drug programs faltered because promising molecules either nudged the wrong levers of cell biology or stalled at the brain’s front door, and the result has been a cycle of costly starts and quiet sunsets that underscored how hard it is to increase autophagic clearance without
